Learn how the pandemic has helped transform RNA as a platform for oncology drug development in this week's episode. We'll be chatting with Myeloid Therapeutics, who are using RNA technology to direct myeloid cells to harness the innate and adaptive immune system for anti-tumour activity.

This week we chat with a guest from Immunocore who specialise in soluble T-cell receptor technology. We'll be diving into their work with KIMMTRAK in uveal melanoma, as well as exciting upcoming studies with PRAME and PIWIL1 across multiple cancer types.

Join us as we speak with Ideaya Biosciences to learn about their latest exciting molecules under development. We'll be covering: promising progress in uveal melanoma with darovasertib (PKCi) + crizotinib; new results in MTAP deficient settings with MAT2Ai + PRMT5i; and next generation molecules for PARPi resistant tumours.